Skip to main content


A vile of Visudyne, a product produced by QLT, in Vancouver November 19, 2004.

Jeff Vinnick/The Globe and Mail

QLT Inc. is cutting 42 per cent of its remaining work force, leaving just 38 employees at the onetime heavyweight in Canada's biotechnology sector.

The Vancouver-based company, which has sold its main product line, said Thursday that its remaining employees after the latest downsizing will be focused on the clinical development of synthetic oral retinoid program.

The plan follows the sale by QLT of Visudyne, its flagship product, to Valeant Pharmaceuticals Inc. for $112.5-million. Visudyne combines an injectable drug and laser light to treat age-related macular degeneration.

Story continues below advertisement

QLT expects to take a $2-million restructuring charge related to the job cuts, said the affected employees will leave during the first half of 2013.

QLT expects to save $3.8-million in annualized expenses once the cuts are fully implemented.

The cuts follow a move by QLT earlier this year to cut 146 of its 214 jobs at the time.

In September, QLT said it planned to buy back up to 3.4 million of its shares over the next year as the first step in a plan to return $100-million to stockholders.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter